$ALT

Altimmune has begun a Phase 3 trial for pemvidutide, a dual-hormone drug targeting metabolic dysfunction-associated steatohepatitis (MASH). The drug uniquely balances glucagon and GLP-1 receptor activation, aiming to address liver fat and fibrosis. The trial's success could validate its differentiation in a crowded market. Altimmune's valuation is highly dependent on the outcome, with a price-to-sales ratio of 72.5x.

$ALT stock rose 7% today with $4.17M in trading volume. Insiders made 6 purchases in the last 6 months. 142 institutional investors increased their positions in Q2 2026. Analysts set price targets ranging from $10 to $20.

Lululemon (LULU), Lucid (LCID), and Altimmune (ALT) hit 52-week lows due to leadership uncertainty, financial strain, and strategic concerns. LULU dropped 13% after naming a new CEO, LCID fell 9% amid funding and production cost worries, and ALT declined 16% following a stock offering. Uber owns 11.52% of LCID.

Durso Jerome Benedict (President and CEO) purchased 15,000 shares of Altimmune, Inc. (ALT) at $2.95 on 2026-08-13.

Altimmune (NASDAQ:ALT) said patients on GLP-1 therapies at antidiabetic doses may be included in its PERFORMA trial, but those on Rezdiffra will be excluded to protect a 52-week biopsy endpoint. PERFORMA 52-week data are expected in 2029. In Phase II AUD RECLAIM, pemvidutide met primary and secondary endpoints, including a 9.1% body-weight reduction. Q2 net loss was $22.8M and cash was $519M.

Altimmune (Nasdaq: ALT) reported Q2 2026 results and a business update. The company initiated the global PERFORMA Phase 3 MASH trial, reported positive topline RECLAIM Phase 2 AUD data, and completed enrollment in the RESTORE Phase 2 ALD trial. Cash, cash equivalents and investments were $519 million as of June 30, 2026. R&D was $18.7 million and net loss $22.8 million.

Altimmune, Inc. (ALT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Altimmune Announces Second Quarter 2026 Financial Results and Business Update ​ Initiated global PERFORMA Phase 3 trial in MASH Reported positive topline data from RECLAIM Phase 2 trial in AUD Completed patient enrollment in RESTORE Phase 2 trial in ALD $519 million

U.S. stock index futures edged higher ahead of July CPI at 8:30 a.m. ET. Economists expect +0.2% m/m and 3.4% y/y. Nasdaq futures were up 0.4% and S&P 500 up 0.1% by 4:00 a.m. ET. Pre-market movers included CRWV (+15%), NBIS (+8%), SMCI (+9%), and ORCL (+1%).

Altimmune (NASDAQ:ALT) reported Phase II results for pemvidutide in alcohol use disorder. The WHO risk-drinking-level endpoint improved in 64.4% vs 34.8% on placebo (p=0.0049), and zero heavy drinking days increased with p=0.0066. PEth fell by 175.3 ng/mL vs unchanged on placebo (p=0.0001). Safety was generally tolerable; Phase III AUD discussions with regulators are next.

Altimmune said its RECLAIM Phase 2 trial of pemvidutide for moderate to severe alcohol use disorder met the primary endpoint, with 2.4 mg producing a statistically significant reduction in heavy drinking days per week versus placebo over 24 weeks (treatment effect 1.45 days). It also met secondary endpoints, and the company plans an End-of-Phase 2 meeting with the FDA. Shares rose 11.5% pre-open.